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Abstract
The Epstein Barr Virus is among the very first oncogenic viruses to be identified as culprits 
of human malignancies. Its role as an etiologic agent of breast cancer however remains 
debated despite mounting molecular evidence. In this chapter we address the challenge 
of multiple molecular etiologies of breast cancer (BC) with emphasis on the Epstein Barr 
Virus (EBV) as a potential causative agent within a frame work of gene/environment inter-
action. We also hope to contribute to a critique of the a concept of universal single agent 
or gene in cancer etiology. In addition to reviewing further reasons of why EBV should 
be considered a tumor virus, coupling molecular targets at the initiation stage, we exam-
ine evidence for the culpability of EBV as oncogenic virus in relation to the genetic and 
epigenetic events that leads to carcinogenesis of cancer; and the subsequent downstream 
interaction including genetic and epigenetic modifiers of signaling and molecular function 
underlying the cancerous phenotype. The TNF family is taken as an example of how the 
epigenetic reprogramming process, impacts molecular targets and how these combined 
interplay of molecular events impinges on pathogenesis and malignancy of breast cancer 
in humans. 
Keywords: Epstein-Barr virus, breast cancer, genetics, epigenetics, microRNA, tumor 
necrosis factor
1. Introduction
1.1. Breast cancer etiology
Although the prevalence of breast cancer (BC) is relatively lower in sub-Saharan Africa com-
pared to that of the “western” countries, it is characterized by aggressive nature and target 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provi ed the origi al work is properly cited.
more women at a younger age [1]. BC etiology is not yet entirely understood, but its incidence 
is thought to be partially explained by environmental factors including viruses such as EBV 
[2]. Recently, a growing pile of evidence has accumulated with regard to the association of 
cancers and viruses. Viruses are believed to cause from 15 to 25% of all malignancies and 
this percentage will increase by more than 50% in 2030 in developing countries [3, 4]. As 
transforming agents, viruses, seem ideal culprit in causing cell transformation. More recently, 
the virus was reported as a main culprit of breast cancer in Sudan [5]. A putative role for 
viruses was speculated based on the limited contribution of mutational events within tumor 
suppressors such as BRCA1, BRCA2, and p53 to breast cancer etiology [6]. Epigenetic silenc-
ing was also envisaged as an obvious candidate to entertain. The fact that methylation lies 
prominently at the interface of genes and the environment, and the known link between self-
ish DNA (viruses) and methylation makes it particularly important in understanding both 
short- and long-term evolutionary effects in oncology. Interestingly, in the same subset of BC 
tissues where fragments of the virus DNA were detected by in situ hybridization in nearly all 
samples, significant epigenetic silencing of tumor suppressers was observed in a limited but 
key set of genes such as BRCA1, BRCA2, and p14 [5].
1.2. Genetic and epigenetic modifiers in breast cancer
A transcriptome study for virus-host interaction identified few of the main partners of EBV 
in the host cell [7] as of oncogenic potential. This is essential for a framework we are propos-
ing in the current chapter. The framework (Figure 1) suggested by us and other authors [8, 
9] entails the involvement of both genetic and epigenetic modifiers to converge on a cancer 
phenotype. However, we propose, in addition, an earlier role for the EBV virus in initiating 
that sequel of events through interaction of viral proteins and nucleic acid with key cellular 
components in the target cell (stem cell). Prominent among these cellular partners are RNA-
binding proteins like ELAVL1/HuR, and editing genes like APOBEC/AID in the genomic side 
and DNMT, TET, and HDAC in the epigenetic side. One significant feature especially in the 
RNA-binding proteins is the plethora of potential targets and partners which could partly 
explain the wide spectrum of biological mechanisms involved and targeted by these events. 
Moreover, the virus molecular interaction could provide a plausible explanation to the fea-
tures of organization described in previous publications [10] and increasingly ascribed to 
DNA/RNA editing and RNA-binding proteins like ELAVL1/HuR in addition to miRNA regu-
lation. ELAVL1 has been reported to show marked centrality in a colorectal cancer family in 
which EBV infection is speculated to have a role [10]. The protein turned to display similar 
centrality among differentially methylated genes in breast cancer cases that had strong EBV 
positivity by in situ hybridization (Figure 2). This does not preclude a role for individual pro-
teins like C-Fos, an established EBV partner [7], which has also been identified as independent 
predictor of decreased survival in breast cancer.
We simply try to differentiate between major upstream effecter molecules and downstream 
by-products of interaction like c-Fos and several other molecules; and cancer as a system and 
polygenic complex phenomenon, versus the rarity of a cancers of Mendelian-like monogenic 
inheritance where one or few molecules are key in determining a tumor phenotype.
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Figure 1. The oncogenic potential of EBV is outlined in the figure, where the interaction of viral proteins and nucleic acid 
(LNP, LNP2, BZLF, etc.) with key cellular components (ELAVL1/Hur, miRNA29) in the target cell (stem cell) dictates 
the consequent pathogenesis and carcinogenesis processes impinged by downstream molecules (e.g., APOBEC3) and 
involving both genetic and epigenetic modifiers.
Figure 2. The centrality of ELAVL1/Hur is demonstrated through an interaction network of differentially methylated 
genes in breast cancer cases with strong EBV positivity using in situ hybridization from Sudan, using the program 
Cognosante.
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2. Breast cancer and EBV
2.1. EBV infection molecular interaction and latency
EBV has been used routinely in laboratories to create cell lines for decades [11]. Furthermore, 
it has been found in breast tissue and is frequently found in breast secretions including breast 
milk [12]. EBV can infect mammary epithelial cells and its DNA fragment (p31) is capable of 
inducing immortalization in these cells [13]. This cosmopolitan γ-herpes virus infects usually 
at younger age. Its main target are B lymphocytes but it has a potential to infect epithelial 
cells as well and thus is associated with various lymphoid and epithelial malignancies and is 
incriminated as a carcinogenic agent by the World Health Organization [14].
EBV is closely associated with endemic Burkitt’s lymphoma in sub-Saharan Africa [15] which 
earned the area the lymphoma belt due to such high frequency among children. The virus is 
associated with a horde of other malignancies in the tropics, such as nasopharyngeal carci-
noma (NPC), gastric cancer, and breast cancer, although most studies regarding the controver-
sial role of the virus as a cofactor in BC were done in countries outside of Africa. The variable 
prevalence of EBV in different regions is an indicator of the importance of the environmental 
and geographic cofactors in the development of such association and the diseases [16].
One key question to be entertained is why some oncogenic viruses like human papillomavirus 
(HPV) and EBV although common infections tend to develop cancer in some individuals whereas 
others remain asymptomatic? Should we speculate population-specific susceptibility factors that 
predispose to cancer in the human genome? Or whether some viral strains have more oncogenic 
potential as the case of HPV16, and 18 and EBV Type I, II and Type III? are there specific role 
and molecular basis of epigenetic silencing in inactivation of tumor suppressors, both of which 
environmental geographical cofactors play an important role in determining the strength of the 
association of malignancy with EBV [17] and hence variation in susceptibility may be influenced 
by factors such as geographical and immunological differences and ethnicity [18, 19].
The natural host of the virus is B-lymphocyte to which the virus gains entry through a type 
two complement receptor (CR2/CD21) [20]. Although breast cancer cells normally do not 
express the receptor CD21 [21], the range of viral tropism could be widened through the 
targeting of stem cells which are capable of expressing a wider range of receptor repertoires. 
EBV can infect primary mammary epithelial cells (MECs) that express CD21 and EBV infec-
tion leads to the expansion of early MEC progenitor cells with a stem cell phenotype, activates 
mesenchymal epithelial transition (MET) signaling and enforces a differentiation block. Hu et 
al. report that EBV can infect primary human mammary epithelial cells (MECs) but not tumor 
cells leading to phenotypic changes consistent with transformation [22]. Latent membrane 
protein-2A (LMP2A) may induce a stem cell state, evidenced by an enhanced self-renewal 
and transformational capacity, and also increases the number of tumor initiating cells in vivo, 
thus potentially rendering a B-lymphocyte into a cancer stem cell. This viral protein plays a 
key role not only in EBV latency and persistence but also in the progression of EBV-associated 
cancers such as NPC in which it was expressed in about half of the samples [23, 24]. It affects 
hedgehog signaling and induces stem cell behavior in epithelial cells [25].
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When MECs were implanted as xenografts, EBV infection cooperated with activated Ras and 
accelerated the formation of breast cancer [22]. A human gene expression signature for MECs 
infected with EBV, termed EBVness, was associated with high grade, estrogen-receptor-neg-
ative status, p53 mutation, and poor survival. In 11/33 EBVness-positive tumors, EBV-DNA 
was detected by fluorescent in situ hybridization for the viral LMP1 and BXLF2 genes [22].
The observations that CD21 was absent on all of the tumor cell lines, none of which became 
infected, and that analysis of the TCGA breast cancer RNAseq data revealed no active tran-
scription of EBV [26, 27] suggest that the EBV DNA detected in a subset of human breast 
cancers, is an inactive remnant of a previously active EBV infection that might have occurred 
in mammary epithelial cells years or even decades prior to cancer formation and which is 
no longer required once malignant transformation has occurred [22]. However, the strong 
EBV signals detected by the in situ hybridization in tumor tissues in the study by Yahia et 
al. [5] while being absent from the safety margin requires some explanation. The presence of 
EBV-DNA and an APOBEC mutational signature correlated with adverse clinicopathological 
features, however, the presence of the virus is not always a requirement for tumor growth, 
consistent with a “hit and-run” mechanism which would also explain why mining of the 
TCGA RNAseq data did not show active transcription of EBV [26, 27].
Following EBV infection, the host cell is affected through different mechanisms pertaining to 
the viral lytic and lysogenic survival strategies. The infection that usually occurs during child-
hood triggers the immune machinery which attempts to clear the virus, and this may probably 
be to its own advantage to control the development of another intruder, the tumor. The major-
ity of the asymptomatic carriers harbor up to 50 EBV genomes per million B cells [28]. A virus 
may trick the host cellular machinery and enter into latency phase. Histone acetylation plays 
an important role in the switch between the lytic and lysogeny phases by regulating BZLF 
promoter known as Z. It has been suggested that the balance between recruitment of histone 
acetyltransferases versus histone deacetylases by transacting factors promotes and decides 
the switch between latency and lytic reactivation [29]. Viral latency may eventuate in carci-
nogenesis provided the presence of conducive host (susceptibility factors) and viral (onco-
genic latency proteins) exists. During latency the virus successfully evade the host’s immune 
system and persists within the B cells by decreasing its contents to few latent genes [30], six 
nuclear antigens, three latent membrane proteins and two abundant untranslated RNAs and 
can persist without being recognized by the immune system and with little interference with 
the health of the host. Functionally, the oncogenic potential of the virus is associated with its 
latency molecules such as latent membrane protein-1 (LMP1) [31], but some studies however, 
reported that this form of the virus (latency) to be associated with good prognosis, while  on 
the other hand its lytic form to be a sign of worse outcome [32]. These, and the authors con-
clude that this might possibly occur through non-specific anti-tumoral immune response and 
they consider the virus as a ‘double faceted’ infectious agent at a time acting as a co-factor for 
the anti-tumoral immune response. However, this is contradicted by the fact that in patients 
with good prognosis high frequency of interferon (IFN)-γ and tumor necrosis factor (TNF)-α 
producing cells were observed, which indicates the existence of a Th1-type polarized immune 
response in the tumor [32]. Inflammation may also contribute to cancerous and precancer-
ous conditions, mainly through signaling of the highly central and pivotal protein NFkB. 
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The mechanism which disturbs this perfect host-virus equilibrium which is indicated by the 
majority asymptomatic carriers is not known yet. It could be inherent in the host or in the 
virus or in both? EBV usually infects immunosuppressed/immunocompromised individu-
als [33]. Most of the post-transplant lymphoproliferative disorders (PTLD) which are more 
common in immunosuppressed transplant patients are EBV-associated [34]. The association 
with PTLD has been observed particularly following allogenic stem cell transplantation (SCT) 
[35], which brings the element of the stem cell factor in EBV-associated cancer [36] and may 
account for receptor promiscuity.
2.2. EBV and APOBEC3 as a genomic modifier
Of the several molecules that confer the spectacularly wide genotypic and phenotypic changes, 
characteristic of the cancer cell is the APOBEC/AID family of enzymes. Editing by apolipopro-
tein B editing catalytic subunits proteins 3 (APOBEC3s) is a strong and well-conserved system 
of the innate immunity that mutates and inactivates viral genomes [37, 38]. These proteins are 
involved in the system of innate defense against exogenous viruses and endogenous retroele-
ments. EBV genomes in EBV-transformed oligoclonal B-cell lines can be edited by at least 
one APOBEC3 enzyme [39]. It is possible that APOBEC3 increases the chance of viral DNA 
integration in the host by inducing mutations and genome instability after viral infection [40].
In an analysis of the TCGA breast cancer data mentioned earlier, EBVness correlated with the 
presence of the APOBEC mutational signature. Recently, APOBEC3 proteins linked the viral 
infections to cancer development [41], and now recognized as key players in cancer-associated 
somatic mutation processes that seem to influence cancer development and progression [42, 43]. 
In breast cancer, APOBEC3B mRNA was found to be overexpressed in the normal breast epithe-
lial cells transfected with HPV [44], indicating a possible role of APOBEC-mediated mutagen-
esis in HPV-driven tumor development [45]. APOBEC3G was found to be highly expressed in 
colorectal tumors and hepatic metastasis, and it has been proposed to promote colorectal cancer 
hepatic metastasis through miR29 downregulation and consequent derepression of MMP2, a 
known metastasis activator [46]. Also, it has been involved in microRNA regulation [47].
Both molecules, APOBEC3 [10] and miRNA [Yousif submitted], have been implicated in 
Sudanese multicase colorectal family, with the striking finding of identify by state of tumor 
tissues between distant relatives, in contrast to a limited similarity between relatives (identity 
by decent).
2.3. EBV as a potential epigenome modifier
The relationship between EBV and the epigenetic machinery particularly methylation of CpG 
moieties is too obvious to oversee. It is embedded in the distant evolutionary relationship of 
viruses and DNA modification systems of selfish DNA. Several tumors are associated with 
arthrobacter luteus (Alu) elements in which tumor suppressor genes are more enriched [48] and 
other markers of selfish DNA including the recently recognized N6-methyladenosine (m6A), the 
most common internal messenger RNA modification found in eukaryotes and also in RNA of 
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nuclear-replicating viruses [49]. This modification is catalyzed by an evolutionarily conserved, 
nuclear, multicomponent enzyme. One of whose subunits, methyltransferase-like 3(METTL3), 
has been identified and a METTL3 knockout model resulted in an apoptosis phenotype [50]. 
The infected and EBV transformed cancer cell employs a bundle of these tools including the 
above, HDAC, methylating enzymes like DNMTA/B to its advantage and survival. Methylome 
analysis may provide further clues to the contribution of epigenetics to the tumorigenesis pro-
cess in dictating the function of key cancer genes and genomes.
DNA hypermethylation in cancer genomes usually occurs in the promoter regions of tumor 
suppressor genes, which can result in silencing of tumor suppressor [51]. In contrast, DNA 
hypomethylation often targets DNA repeats, which may induce genomic instability and muta-
tion events in cancer genomes [52]. There is evidence that promoter hypomethylation of some 
genes may be associated with the tumor progression and metastasis of some cancers [53] as 
well as the initiation of inflammation and immunomodulation [54].The role of DNMT3B in 
the altered methylation and inactivation of genes in human tumor cells as well as its role in 
the maintenance of the transformed phenotype is well established. It has significant site selec-
tivity that is distinct from DNMTA1, regulates aberrant gene silencing, and is essential for 
cancer cell survival [55]. DNMT3A and DNMT3B repress transcription independent of their 
methylating activities, and this repression is partially dependent upon histone deacetylase 
activity (HDAC) [56]. DNMT3B-mediated gene suppression may involve both methylation-
dependent and methylation-independent HDAC-dependent mechanisms. Histone acetyla-
tion, a component of an epigenetic mechanism has a role in the initiation and progression of 
human cancer as a result of post transcriptional modification [57]. Aberration in HDACs leads 
to transcriptional repression in genes involved in proliferation, differentiation, invasion, and 
metastasis [58]. HDAC9 an important factor in mammary carcinogenesis [59] overexpression 
was associated with higher rates of gene transcription and increased epigenetic marks on the 
HDAC9 promoter. Methylome of BC is a foundation for metastatic risk “CpG island meth-
ylator phenotype (CIMP)” in breast cancer is not yet clearly defined as is in colon cancer, in 
which it is defined by promoter hypermethylation of at least three of five specific methylation 
markers [60]. In one study, lobular breast carcinoma was revealed with the highest number 
of differentially methylated CpG sites indicating its epigenetic unstableness [61]. EBV pro-
tein, LMP2A, can cause activation of (DNMT1), which in turn hypermethylate a tumor sup-
pressor gene, PTEN in EBV-associated gastric cancer [62]. DNMT1 over expression mediated 
by EBV LMP1 and LMP2 and Oncogenic EBV gene, LMP1, can upregulate all of the DNA 
methyltransferases (DNMTs) [63]. DNMT3b overexpression contributes to a hypermethylator 
phenotype in human breast cancer cell lines [64], and LMP2a functions in the initiation and 
progression of cancer by inducing the cancer stem-like cells [24] as aforementioned.
Differential methylation analysis of whole methylome data of breast cancer cases from Sudan 
provided a possible link between these entities. The results reveal epigenetic dysregulation of 
major developmental pathways including hippo signaling pathway [Alsiddig, 2015, data online, 
pending submission], thus providing not only a clue to the stem cell dimension of the disease 
but also insights to subsequent pathognomonic features of cancer process. It also demonstrated 
the presence of significant enrichment of EBV-associated pathways with a significant score.
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3. TNFα gene methylation
An insightful example of the contribution of the methylation phenotype to breast cancer 
through modulation of key cancer-related genes is the TNFα. Genetic as well as epigenetic 
aberrations at the promoter of TNF-α has been reported; its promoter can be methylated with 
functional modification, and eight DNA variants or “SNPs” have been described within the 
TNF promoter as reviewed by Bayley et al. [65].
Methylated TNFα promoter and TNFα exon1 were associated with significant suppression 
of TNF in colorectal tumors [66], although, this has to be reconciled with a contrasting report 
of TNF-α shown to be highly expressed in breast carcinomas [67]. TNF-α is a multifunctional 
cytokine that plays important roles in diverse cellular events such as cell survival, proliferation, 
differentiation, and death. However, when chronically produced and inflammation persists in 
the tumor microenvironment it may have a critical role in the promotion and progression of 
cancers by DNA damage, enhancing proangiogenic functions, increasing the expression of 
matrix metalloproteinases (MMP) and endothelial adhesion molecules and inducing growth-
promoting hormones and chemokines that promote tumor development [68]. TNF-α can 
promote EMT of MCF-7 cells and activates cell migration [69]. This transition generates stem-
cellness [70]. Activation of regulatory T cells (Tregs) can cause immunosuppression and has 
resulted from prolonged exposure to TNF-α [71], which could have a cancer-promoting effect. 
TNF is hence believed to be a double-edged sword that could be either pro- or antitumorigenic, 
this double standard phenomenon is also seen in severe infectious diseases such as malaria 
in which fatal cerebral malaria is associated with high circulating levels of this cytokine [72]. 
Environmental factors such as malaria exerts selective pressure on the TNF loci and is reflected 
on common polymorphisms in the human genome like the TNF (–308G/A) in the TNF pro-
moter (–308G/A). This SNP which was found to be associated with protection from malaria [72] 
was found to be associated with susceptibilities to various types of cancer [73]. This influence 
on the susceptibility to cancer may be associated with altered TNF production or a neighboring 
gene in tight-linkage disequilibrium. These reports indirectly suggest that TNF has a tumor-
promoting role and that TNF promoter SNPs could be a predictor for cancer risk.
The CD40 ligand (CD40L), a glycoprotein involved in B cell proliferation, antigen presenting 
cell activation, and member of the TNF receptor ligand family, was reported to confer pro-
tection from severe malaria has also significant functional homology with EBV LMP1. In the 
malaria endemic area of eastern Sudan, elevated levels of CD40L expression were observed in 
comparison to naive healthy controls from nonmalaria areas.
In an analysis of the methylome of subset of human triple-negative breast cancer the analy-
sis identified significant enrichment in methylation phenotypes of the tumor necrosis factor 
(TNF) and TNF receptor family (Table 1). The attempts to dissect the functionality of the TNF 
promoter have all concentrated on the genetic aspects of TNF gene regulation, but now with 
the increasing interest in the epigenetic control of gene regulation and possible significance 
for disease, it is surprising that little attention has been paid to the possibility that aberrant 
methylation could play a role in TNF dysregulation.
TNF-α stimulates many signaling pathways by binding to two receptors, TNFR1 (p55) and 
TNFR2 (p75) [68, 74]. TNFR-1 is ubiquitously expressed, whereas TNFR-2 is mainly expressed 
in immune cells [75].
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4. Gene chromosome location and breast cancer
Another key class of molecules identified through this approach is the hypomethylated olfac-
tory receptor genes in Sudanese breast cancer samples. Significant enrichment of differentially 
hypomethylated olfactory receptor family members were mapped to chromosomes 1 specifi-
cally to chr1q44 (P-value, 6.867e-20) a cytoband known to be one of the viral integration sites 
[76]. Moreover, this location is also associated with autoimmune diseases [77] and chronic 
inflammatory responses induced by physical stimuli from the environment [78]. It seems that 
the virus selects this environmentally prone site.
Gene symbol Site of hypermethylation Site of hypomethylation
TNF TSS 1500, promoter –
TNFRSF1A Body –
TNFAIP3 Body –
TNFRSF1B Body –
TNFSF11 5’ UTR, promoter, exon 5’ UTR, promoter
TNFRSF10D Exon, body, promoter Body
TNFAIP8L1 TSS1500, promoter –
TNFRSF19 5’ UTR, exon, body, promoter, –
CIQTNF4 5’ UTR, body, promoter Exon
C1QTNF5 5’ UTR, body, 3’ UTR, promoter –
TNFRSF13C TSS1500, promoter –
C1QTNF9 TSS1500, promoter –
TNFRSF13B TSS1500, promoter –
TNFRSF11A TSS1500, promoter Body
TNFRSF8 Promoter –
C1QTNF7 Exon –
TNFAIP8L3 Body –
C1QTNF1 Body –
TNFSF12-TNFSF13 Body –
TNFSF8 – Body
TNF18 – Body
C1QTNF6 – Body
C1QTNF8 – 3’ UTR
Table 1. Differentially methylated TNF and TNF receptor family genes at various CpG sites from Sudanese breast cancer 
samples, indicating the significant enrichment in methylation phenotypes in this important family of genes and being a 
target of epigenetic modification in a directed tumorigenesis process.
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According to various studies, chromosome 1 aberration is associated with different cancers, 
such as neuroblastoma [79], cervical [80], and colorectal [81]. In breast cancer, gains at 1q are 
found in over 50% of breast tumors [82]. It is reported that the long arm of chromosome1 to be 
usually associated with karyotypic changes seen in breast cancer and is believed that the devel-
opment of breast cancer might be caused by inactivation of a gene (s) located on 1q23-32 [83].
5. miRNA as epigenetic actor in breast cancer
microRNA(miRNA) is naturally involved in the biological process across the carcinogenesis 
from initiation to metastasis and this occurs through the spectrum of genetic and epigenetic 
mechanisms of the cell. Several miRNA have been reported to be involved in the myriad 
of the biological processes, for example miR-22 (chromosome 17) can regulate breast cancer 
stemness and metastasis through a TET-dependent chromatin remodeling [84], and miR-373, 
miR-520 were found to promote migration and invasion of BC cells.
A differential analysis of the methylome dataset of a Sudanese breast cancer cases and controls 
identified hypomethylated sites for six different miRNAs, including miR-153-2, miR-2276, 
miR-30B, miR-1204, miR-141, and miR-300 [Alsiddig, 2015 data on line, pending submis-
sion]. Only miR-153-2, miR-2276, and miR30B had been previously associated with breast 
cancer [85–87]. miR153-2 was of particular interest, since numerous studies linked miR153 to 
a myriad of epithelial cancers. One study demonstrated that miR-153 upregulation promotes 
prostate cancer proliferation through downregulation of PTEN tumor suppressor gene [88].A 
test dataset The Cancer Genome Atlas (TCGA), contained methylation data for 90 samples 
of healthy individuals and 638 samples of primary tumor. The authors found miR153-2 pro-
moter to be significantly hypomethylated at the exact same CpG sites. Interestingly, another 
epigenetic regulators, TET2, and TET3 are among the listed targets of miR153-2 as predicted 
by TargetScan algorithm.
RNA-binding protein sometimes have the same target sequence as miRNA and a notable 
example is miRNA 29 which competes with ELAVL1 on the same regulatory sites.miRNA29b 
Stops protein production from other genes that play vital role in metastasis and its isoform are 
shown to regulate various aspects of the carcinogenesis process in different tumors. However, 
its target site homology with a key RNA-binding protein like ELAV1/Hur suggest that this 
micro RNA may play a critical role in the early phase of viral pathogenesis and in coupling of 
downstream key players like TNFα as shown in Figure 1.
6. Conclusion
In this chapter, we review some examples pertinent to questions as of why EBV should be 
considered a tumor virus, examine molecular evidence for the culpability of EBV as onco-
genic virus in relation to the established cases of EBV cancer oncogenesis; the cancer target 
cell and stem cell, which bring the element of development as an epigenetic reprogramming 
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process, linking the breast cancer methylome differential methylation to developmental and 
EBV, dwelling on EBV molecular targets, and how the combined interplay of molecular events 
in human impinges on pathogenesis and malignancy of breast cancer.
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